Request Demo
Recent blog posts
Latest Hotspot
8 min read
Visceral leishmaniasis Indication Strategy Report 2026: Leishmania CYP51, Trials and Deals
23 July 2026
2026 Visceral leishmaniasis strategy: epidemiology, Leishmania CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cutaneous leishmaniasis Indication Strategy Report 2026: Leishmania CYP51, Trials and Deals
23 July 2026
2026 Cutaneous leishmaniasis strategy: epidemiology, Leishmania CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Toxoplasmosis Indication Strategy Report 2026: Toxoplasma DHFR, Trials and Deals
23 July 2026
2026 Toxoplasmosis strategy: epidemiology, Toxoplasma DHFR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Babesiosis Indication Strategy Report 2026: Babesia DHODH, Trials and Deals
23 July 2026
2026 Babesiosis strategy: epidemiology, Babesia DHODH biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Onchocerciasis Indication Strategy Report 2026: Wolbachia, Trials and Deals
23 July 2026
2026 Onchocerciasis strategy: epidemiology, Wolbachia biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Schistosomiasis Indication Strategy Report 2026: Sm14, Trials and Deals
23 July 2026
2026 Schistosomiasis strategy: epidemiology, Sm14 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
African trypanosomiasis Indication Strategy Report 2026: Trypanosoma protease, Trials and Deals
23 July 2026
2026 African trypanosomiasis strategy: epidemiology, Trypanosoma protease biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lymphatic filariasis Indication Strategy Report 2026: Wolbachia, Trials and Deals
23 July 2026
2026 Lymphatic filariasis strategy: epidemiology, Wolbachia biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Chagas disease Indication Strategy Report 2026: Trypanosoma cruzi CYP51, Trials and Deals
23 July 2026
2026 Chagas disease strategy: epidemiology, Trypanosoma cruzi CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Leishmaniasis Indication Strategy Report 2026: Leishmania CYP51, Trials and Deals
23 July 2026
2026 Leishmaniasis strategy: epidemiology, Leishmania CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary membranous nephropathy Indication Strategy Report 2026: PLA2R, Trials and Deals
23 July 2026
2026 Primary membranous nephropathy strategy: epidemiology, PLA2R biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Familial renal glucosuria Indication Strategy Report 2026: SGLT2, Trials and Deals
23 July 2026
2026 Familial renal glucosuria strategy: epidemiology, SGLT2 biology, clinical competition, recent deals, unmet need and market attractiveness.